Akebia Therapeutics, Inc. (FRA:AX9)

Akebia Therapeutics Statistics

Total Valuation

FRA:AX9 has a market cap or net worth of EUR 344.68 million. The enterprise value is 372.70 million.

Market Cap	344.68M
Enterprise Value	372.70M

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	265.37M
Shares Outstanding	n/a
Shares Change (YoY)	+20.49%
Shares Change (QoQ)	+1.21%
Owned by Insiders (%)	2.01%
Owned by Institutions (%)	48.97%
Float	260.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	13.82
PS Ratio	1.80
PB Ratio	9.72
P/TBV Ratio	n/a
P/FCF Ratio	12.57
P/OCF Ratio	12.48
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of 13.59.

EV / Earnings	-27.49
EV / Sales	1.93
EV / EBITDA	11.63
EV / EBIT	19.74
EV / FCF	13.59

Financial Position

The company has a current ratio of 1.94, with a Debt / Equity ratio of 4.78.

Current Ratio	1.94
Quick Ratio	1.74
Debt / Equity	4.78
Debt / EBITDA	5.34
Debt / FCF	6.19
Interest Coverage	0.84

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	4.80%
Return on Invested Capital (ROIC)	9.35%
Return on Capital Employed (ROCE)	9.51%
Revenue Per Employee	1.06M
Profits Per Employee	-74,894
Employee Count	181
Asset Turnover	0.79
Inventory Turnover	1.92

Taxes

In the past 12 months, FRA:AX9 has paid 524,165 in taxes.

Income Tax	524,165
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.42%
50-Day Moving Average	2.01
200-Day Moving Average	2.34
Relative Strength Index (RSI)	32.90
Average Volume (20 Days)	3,005

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.28

Income Statement

In the last 12 months, FRA:AX9 had revenue of EUR 191.83 million and -13.56 million in losses. Loss per share was -0.06.

Revenue	191.83M
Gross Profit	159.83M
Operating Income	18.71M
Pretax Income	-13.03M
Net Income	-13.56M
EBITDA	27.48M
EBIT	18.71M
Loss Per Share	-0.06

Balance Sheet

The company has 141.86 million in cash and 169.61 million in debt, giving a net cash position of -27.75 million.

Cash & Cash Equivalents	141.86M
Total Debt	169.61M
Net Cash	-27.75M
Net Cash Per Share	n/a
Equity (Book Value)	35.45M
Book Value Per Share	0.13
Working Capital	106.50M

Cash Flow

In the last 12 months, operating cash flow was 27.61 million and capital expenditures -190,063, giving a free cash flow of 27.42 million.

Operating Cash Flow	27.61M
Capital Expenditures	-190,063
Free Cash Flow	27.42M
FCF Per Share	n/a

Margins

Gross margin is 83.32%, with operating and profit margins of 9.75% and -7.07%.

Gross Margin	83.32%
Operating Margin	9.75%
Pretax Margin	-6.79%
Profit Margin	-7.07%
EBITDA Margin	14.33%
EBIT Margin	9.75%
FCF Margin	14.30%

Dividends & Yields

FRA:AX9 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.49%
Shareholder Yield	-20.49%
Earnings Yield	-3.93%
FCF Yield	7.96%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:AX9 has an Altman Z-Score of -4.06 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.06
Piotroski F-Score	5